Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.66 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.66 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.66 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 10/20 | 0.60 |
| ▸ | CA2 | P00918 | 10/20 | 0.60 |
| ▸ | CA5A | P35218 | 10/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15172850 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1696817 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2385301 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2387335 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL4484995 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1362019 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL12705857 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL10000728 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL5960692 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL863312 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1082291-B1 | CHEMICAL PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF R-(-)-CARNITINE | SIGMA TAU IND FARMACEUTI (IT) | 2004-09-08 | — | — | EP | claimed |
| US-6420599-B2 | CHARACTERIZING STEP IS THE CONDENSATION OF GLYCEROL WITH (-)CAMPHORSULFONAMIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-07-16 | — | — | US | claimed |
| US-20010003135-A1 | Chemical process for the stereoselective synthesis of R-(-)- carnitine | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-07 | — | — | US | claimed |
| CN-116554066-A | Method for synthesizing N- (hetero) aryl sulfonamide compound | 陕西师范大学 | 2023-08-08 | — | — | CN | disclosed |
| EP-3172264-B1 | NOVEL POLYMERS CONTAINING GRAFTED BIS(SULFONYL)IMIDE SODIUM OR LITHIUM SALTS TO THE METHODS FOR THE PRODUCTION THEREOF, AND TO THE USES OF SAME AS ELECTROLYTES FOR BATTERIES | CDP INNOVATION (FR) | 2021-06-16 | — | — | EP | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10141603-B2 | Polymers containing grafted bis(sulfonyl)imide sodium or lithium salts, methods for production thereof and uses of same as electrolytes for batteries | CPD INNOVATION (FR) | 2018-11-27 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20070010676-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO VENTURES I, LLC | 2007-01-11 | — | — | US | disclosed |
| US-7084275-B2 | Stereospecific enrichment of heterocyclic enantiomers | R. T. ALAMO VENTURES I, LLC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040215016-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO VENTURES I, LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1082291-B1 | CHEMICAL PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF R-(-)-CARNITINE | SIGMA TAU IND FARMACEUTI (IT) | 2004-09-08 | — | — | EP | disclosed |
| US-6649764-B2 | Racemization of flusequinan using triphenylphosphine and 10-camphorsulfonyl-oxaziridine to form racemic mixtures | R. T. ALAMO VENTURES I, LLC | 2003-11-18 | — | — | US | disclosed |
| US-20030120075-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO ADVENTURES I, LLC | 2003-06-26 | — | — | US | disclosed |
| US-6420599-B2 | CHARACTERIZING STEP IS THE CONDENSATION OF GLYCEROL WITH (-)CAMPHORSULFONAMIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-07-16 | — | — | US | disclosed |
| US-20010003135-A1 | Chemical process for the stereoselective synthesis of R-(-)- carnitine | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003135-A1 | Chemical process for the stereoselective synthesis of R-(-)- carnitine | CRAT, COASY, CPT1B | KMT2A 3280/4885F2 3975/4885PRSS1 947/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | KMT2A 231/4885F2 2807/4885PRSS1 4055/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | KMT2A 2696/4885F2 156/4885PRSS1 2858/4885 |
| US-20070010676-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, CBR1, QDPR | KMT2A 3308/4885F2 4715/4885PRSS1 3585/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | KMT2A 415/4885F2 4718/4885PRSS1 1451/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | KMT2A 231/4885F2 2807/4885PRSS1 4055/4885 |
| US-20040215016-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, POR, CBR1 | KMT2A 3103/4885F2 4694/4885PRSS1 3447/4885 |
| US-20030120075-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, POR, CBR1 | KMT2A 3103/4885F2 4694/4885PRSS1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.